Disease Landscape and Forecast Insights

Generalized-onset seizures (GOS) simultaneously affect both sides of the brain and rapidly engage bilaterally distributed networks. Nearly 40% of the diagnosed epilepsy population presents with…

Attention-deficit/hyperactivity disorder (ADHD) is one of most common pediatric disorders and one that can continue into adulthood. For decades, pediatric ADHD has been treated primarily with…

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder involving significant social, communication, and behavioral challenges. Behavioral and developmental therapies are the…

To determine the trade-offs across key biosimilar attributes that surveyed medical oncologists are willing to make when considering which biosimilar to prescribe, we included an adaptive choice-…

Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine to launch in Europe and the United States, followed by Sanofi’s Admelog / Insulin…

The figure titled “Rheumatology biosimilars Target Product Profile: attribute importance” shows the relative importance of each of the seven attributes included in the study, derived from the…

In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…

Bipolar disorder (BPD) is a chronic illness characterized by recurrent episodes of aberrant mood; patients may exhibit manic, depressive, or mixed symptoms between periods of stable mood. Treatment…

Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity to…

Hormonal therapy is the cornerstone of drug treatment for prostate cancer in all patient populations. Abiraterone and Xtandi (Pfizer / Astellas Pharma) dominate the metastatic castrate-resistant…